B
Bull
Bull · 25%ABP
$0.24
Scenario price
$0.522
-0.181 (-34.76%)At close
Loading chart…
- High
- 0.780
- Open
- 0.759
- VWAP
- 0.61
- Vol
- 3.26M
- Mkt Cap
- —
- Low
- 0.517
- Amount
- 1.98M
- EV/EBITDA, TTM
- 0.00
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
AI analysis of ABPRO Holdings Inc (ABP)
sellABPRO Holdings Inc (ABP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or strong trading signals to justify a buy decision.
Valuation Metrics
The current forward P/E ratio for ABPRO Holdings Inc (ABP) is -0.63, compared to its 5-year average forward P/E of -1.48.
Alphio AI Price Scenarios for ABP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
9.502-12BenzingaFastly Reports Strong Quarterly Earnings Exceeding Expectations
4.502-10BenzingaU.S. Stocks Mixed in Morning Trading
9.502-10BenzingaCredo Technology Raises Revenue Guidance Significantly
9.012-15GlobenewswireAbpro Submits IND for ABP-102/CT-P72, Initiating Phase 1 Clinical Trial
9.012-15NewsfilterAbpro Submits IND Application for ABP-102/CT-P72, Targeting HER2-Positive Cancers
ABP FAQ — answered by Alphio AI
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD). It operates in the Healthcare sector.
ABPRO Holdings Inc (ABP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or strong trading signals to justify a buy decision.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.